Method and apparatus for delivery of cell therapy to intima, subintimal space, media, adventitia, periadventitial space, or perivascular tissue from inside of blood vessel lumen, or from adjacent blood vessel lumen
The method and device deliver stem cell suspensions to the intima, subintimal space, and periadventitial space using balloons or thin tubes with spikes, addressing the challenge of retaining cells at the vascular injury site and treating intimal hyperplasia and aneurysms effectively.
Patent Information
- Application Number
- JP2024147155
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-11-02
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for intimal hyperplasia and aneurysms face challenges in delivering freshly prepared stem cell suspensions to the site of vascular injury or surrounding tissue, as existing devices are unsuitable and stem cells are easily swept away by blood flow, while existing drug-coated devices are ineffective against the complex mechanisms of these conditions.
A method and device for delivering cell therapy via percutaneous access, allowing stem cell suspensions to be introduced from within the lumen of a blood vessel to the intima, subintimal space, media, adventitia, or periadventitial space, using balloons or thin tubes with spikes or helix structures to penetrate the plaque layer and retain cells at the treatment site.
Effectively delivers stem cells to the site of vascular injury or surrounding tissue, preventing restenosis and treating aneurysms by maintaining cell viability and ensuring retention at the intervention site, overcoming the limitations of existing drug-coated devices.
Smart Images

Figure 2024161609000001_ABST
Abstract
Description
[Background technology]
[0001] This application claims priority to U.S. Provisional Patent Application No. 62416189, filed November 2, 2016.
[0002] Cardiovascular disease is the leading cause of death worldwide. Atherosclerosis can lead to symptomatic occlusion of major coronary arteries causing angina and myocardial infarction. The most common treatments include bypass surgery, atherectomy, and balloon angioplasty combined with implantation of a stent. Intimal hyperplasia is the most common failure mode of atherectomy, angioplasty, and stenting. This major problem occurs after all percutaneous coronary interventions and results in associated restenosis of the coronary artery at a high rate of 15-30% within the first year. Intimal hyperplasia consists of the accumulation of vascular smooth muscle cells migrating into the intimal portion, as well as the deposition of extracellular matrix material. This results in a decrease in the luminal diameter of the affected vessel, resulting in end-organ ischemia. The importance of treating the cause of intimal hyperplasia to prevent restenosis is evident in its prevalence and in the myriad of devices and treatments that have been proposed to address this problem.
[0003] Early treatments were attempts to prevent restenosis after angioplasty due to intimal hyperplasia through the development of stents. These treatments failed because intimal hyperplasia grew through the holes in the stent. Covered stents were then developed to prevent this, but intimal hyperplasia developed at the ends of the covered stent, causing restenosis. More recent treatments attempt to address specific steps or factors in the process of intimal hyperplasia. Their lack of success can generally be attributed to the complex mechanisms involved in the development of intimal hyperplasia, and the difficulty of providing effective treatment. Causes of intimal hyperplasia include hemodynamic factors such as shear stress and wall tension, injury including endothelial denudation and medial tears, inflammation, and genetic factors. Each of these causes is associated with complex pathways and various cells and chemical mediators. A number of drug therapies have been developed to attempt to reduce the development of intimal hyperplasia by targeting specific steps or cells in specific pathways or by minimizing the initial cause.
[0004] Current therapies for reducing intimal hyperplasia include the use of drug-eluting stents and drug-eluting angioplasty balloons. Some of these stents and balloons are coated with various drugs that migrate from the stent or balloon surface upon direct contact or intervention with the angioplasty site. Others allow for the release of drugs near the vessel wall. The drugs then come into contact with the vascular tissue and exert their inhibitory effect on the hypertrophic scar reaction (intimal hyperplasia) with the goal of reducing the likelihood of recurrent occlusion at the treatment site.
[0005] The prior art contains many examples of devices for delivering drugs to blood vessels, among them U.S. Patent No. 5,087,244 to Wolinsky et al., U.S. Patent No. 5,985,307 to Hanson et al., and U.S. Patent No. 7,985,200 to Lary et al.
[0006] Another significant vascular disease condition is ruptured aneurysm, which is the leading cause of death worldwide. Currently, treatment is surgical resection or ablation, and there is no therapy to prevent or halt the disease. The pathophysiology of aneurysmal disease has been demonstrated to be degeneration of the artery with a significant inflammatory component. The inflammatory process is located in the arterial wall and the surrounding periadventitial fat and tissue.
[0007] Prior art for the preparation and use of adipose-derived stem cells includes U.S. Pat. No. 8,691,216 to Fraser et al. and U.S. Pat. No. 9,198,937 to Fraser et al., in which such stem cells are used to promote wound healing and liver injury by delivery via a balloon-equipped catheter.
[0008] Recently, it has been shown that intimal hyperplasia can be reduced by the introduction of stem cells from outside the vessel to the site of angioplasty-induced arterial injury. (Inhibitory Effects of Mesenchymal Stem Cells in Intimal Hyperplasia After Balloon Angioplasty, Ae-Kyeong Kim,PhD,a Min-Hee Kim,a Do-Hyung Kim,a Ha-Nl Go,a Seung-Woo Cho,PhD,b Soong Ho Um,PhD,c and Dong-Ik Kim,MD,PhD,http: / / dx.doi.org / 10.1016 / j.jvs.2014.08.058)
[0009] It is also believed that stem cell therapy may be a potential drug therapy for aneurysms. Delivery systems for cell therapy are not currently available or suitable for the treatment of aneurysmal disease. The fragility of diseased arterial walls presents a special challenge to the delivery of therapy with the risk of manipulation of the aneurysmal tissue during treatment.
[0010] Finally, it is believed that stem cell therapy can be used as a medical treatment for other disease conditions, provided that the cell suspension may be delivered directly to the vicinity of the tissue in need of treatment, and delivery via the circulatory system using percutaneous access is desired.
[0011] No device has been developed or commercialized to deliver cell therapy to the lumen of a blood vessel for this type of application. The difference between current drug-coated interventional devices and cell therapy is that to be viable, the stem cells must be freshly prepared and maintained in suspension (as opposed to being coated onto the interventional device and maintained dry for storage). A further difference is that stem cells (and other cell suspensions) are large in size compared to drug molecules, and are swept away from the intervention site by the blood flowing through the blood vessels after the procedure is completed. Thus, new methods are needed to deliver appropriately prepared fresh liquid suspensions of stem or non-stem cells to the intervention site and maintain them there. Summary of the Invention
[0012] The disclosed invention is a method and device for the delivery of cell therapy introduced via percutaneous access to the circulation and delivered to the site of vascular injury or intervention or to the surrounding tissues. The cell suspension is delivered from within the lumen of a blood vessel to the intima, subintimal space, media, adventitia or periadventitial space, or from within the lumen of an adjacent blood vessel to the tissue and fat surrounding the artery. [Brief description of the drawings]
[0013] [Figure 1] FIG. 1 shows a cross-sectional view of one embodiment of a delivery device of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] A preferred embodiment of the present invention is a balloon carrying one or more tubes with openings or continuous grooves on its surface. Upon expansion to disrupt the plaque layer, a cell suspension is introduced through the tubes where it flows from the openings (or grooves) into the vessel wall. This embodiment may also include a central passage to allow blood flow during expansion. The medium in which the cells are suspended may be a biologically neutral or active solution, and may optionally contain drugs, biologicals, and other additives.
[0015] The delivery device of the present invention shown in FIG. 1 is a toroidal balloon (10) having a hollow rigid spike (30) on its outer surface (20). The balloon is attached to a conventional catheter (not shown) for percutaneous access to the blood vessel being treated and is placed in the blood vessel in an uninflated or minimally inflated state. The inner wall (25) of the toroidal balloon may be made of a relatively stiff material to facilitate insertion and placement of the balloon. Once placed, the balloon may be inflated by introducing a cell suspension under pressure, expanding the balloon (10) and forcing the hollow rigid spike (30) into and through the plaque layer, delivering the suspension through the spike to the desired structure of the plaque and / or blood vessel wall. The balloon (10) is then deflated and withdrawn, leaving the stem cells behind but not swept away in the bloodstream. Because the balloon (10) is toroidal, it does not block blood flow through the blood vessel being treated.
[0016] In an alternative embodiment (not shown), the balloon (10) may be spherical or elongated, but not toroidal, and during inflation, block blood flow through the blood vessel being treated. The balloon (10) may optionally be provided with annular flanges (not shown) at the proximal and distal ends. These flanges engage the vessel wall and serve to impede blood flow between the vessel wall and the outer surface (20), instead directing blood flow through a torus.
[0017] The method of the present invention for the treatment of intimal hyperplasia requires that the plaque layer in the blood vessel to be treated is disrupted or penetrated, and that a suspension of stem cells or non-stem cells is delivered from beneath the plaque to the intima, subintimal space, media, adventitia, and / or peradventitial space. Disruption of the plaque may be by balloon inflation, as commonly seen in angioplasty, or by other mechanical means, such as compression of a stent-like device to increase its diameter after placement in the vessel. Disruption of the plaque may be by conventional means, such as balloon inflation, prior to and separate from the introduction of the stem cells according to the present invention, or may be combined into a single device that disrupts the plaque and then introduces the cell suspension. Penetration of the plaque may be by extending a spike or similar structure after placement of the delivery device of the present invention in the vessel. In either case, after disruption or penetration, the suspension of stem cells is delivered with sufficient pressure to move the cells into the plaque layer and / or one or more selected structural layers of the blood vessel being treated, remaining after removal of the delivery device.
[0018] Another alternative embodiment of the delivery device of the present invention (not shown) is a spiral or double spiral structure of thin tube with small openings spaced along the length of the tube. Similar in appearance to a conventional stent, the device is inserted into the vessel using a catheter and positioned as desired. The device is then withdrawn together (by the movement of a conical member, not shown) to increase its diameter, thereby being used to fracture the plaque layer, and is embedded deep within the plaque. Alternatively, the device may be formed from a shape memory metal that expands when released from a constraining sheath or when heated to body temperature. A catheter is then used to introduce a cell-based suspension into the tube, which exits the tube through the small openings. After introduction of the stem cells, the device is elongated to reduce its diameter, dislodging it from the vessel wall, and withdrawn together with the catheter.
[0019] Yet another embodiment is a multi-lobed balloon with small openings or hollow spikes at the apex of each lobe that contact the vessel wall.
[0020] Yet another embodiment is a multi-lobed balloon with one or more openings in the inter-lobular spaces that define channels that can be filled with a cell suspension, providing an increased contact area between the plaque layer and the suspension. In this embodiment, an annular flange is used to confine the cell suspension and direct blood flow through a central hollow lumen within the balloon, or through an alternative channel on the outer surface of the balloon, as described above. The annular flange then has openings or notches that communicate with such channels or central lumen.
[0021] Each of the above balloons may of course be of a dual lumen design to allow for delivery and inflation to the vessel wall using a different fluid separate from the cell suspension.
[0022] For interventions aimed at treating aneurysms, the aforementioned cell suspension delivery system, capable of penetrating the venous wall completely, can be used for delivery of cell therapy directly to the surrounding periarterial tissue and fat in the aneurysmal arterial wall. Most arteries are adjacent to paired veins. The cell suspension delivery device is inserted through the adjacent vein and deployed within the vein. Once deployed, hollow spikes on the device penetrate through the venous wall into the tissue surrounding the aneurysmal artery. The cell preparation is delivered through the spike, after which the device is retrieved and removed. Alternatively, the cell preparation may be delivered via a catheter intended to contact and support the venous wall. Once in contact with the wall, one or more multiple needles, or spikes, can be positioned and the injection delivered to the periarterial tissue.
[0023] While the present invention has been described in its preferred embodiment, it should be understood that the terms used are terms of description, not of limitation, and that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the invention in its broader aspects. Rather, various changes in details may be made within the scope of the claims' equivalents without departing from the spirit of the invention. The inventors further request that these claims be conformed to the broadest construction available under the law existing at the filing date of this application (and the filing date of the application to which this application derives priority, if any), and that any such restriction due to a later change in law will not be permitted, since such restriction is a retroactive award and an expropriation without due process and compensation.
Claims
1. A cell suspension delivery device comprising: an outer deformable member having an outer surface carrying a plurality of protrusions for perforating one or more layers of the blood vessel (including a plaque layer) when positioned within the lumen of the blood vessel; and an inner surface defining an internal cavity, each protrusion having a bore in fluid communication with the internal cavity and having a diameter sufficient to allow cells suspended in a liquid medium to pass from the internal cavity through the bore and into the plaque layer, one or more layers of the blood vessel, or perivascular tissue.
2. The cell suspension delivery device of claim 1 , further comprising a catheter connected to the device, the catheter having an inner lumen in fluid communication with the interior cavity.
3. 2. The cell suspension delivery device of claim 1, further comprising an inner member joined to the outer deformable member defining a torus having a toroidal cavity, an inner surface and an outer surface, the protrusions being located only on the outer surface outside the toroidal cavity.
4. The cell suspension delivery device of claim 3 , further comprising a catheter connected to the device, the catheter having an inner lumen in fluid communication with the interior cavity.
5. The cell suspension delivery device of claim 3 , wherein the inner member defines a non-deformable toroidal cavity.
6. 2. The cell suspension delivery device of claim 1, wherein the protrusion penetrates one or more layers of a blood vessel and surrounding tissues selected from the group of layers including plaque, intima, subintimal space, media, adventitia, per-adventitial space, and perivascular tissue.
7. The cell suspension delivery device of claim 1 , wherein the protrusions are of two or more lengths.
8. The cell suspension delivery device of claim 1 , wherein the protrusion is extendable and retractable.
9. A cell suspension delivery device comprising a tubular member having a longitudinal axis and a radial axis, an inner lumen and an outer surface, the tubular member having one or more openings of sufficient diameter to allow cells suspended in a liquid medium to pass from the inner lumen to the openings, the tubular member being flexibly deformable to increase its radial dimension a distance sufficient to cause disruption of the plaque layer in a blood vessel into which the device is introduced.
10. 10. The cell suspension delivery device of claim 9, wherein the tubular member is deformed by the inflation of a balloon centrally located in the blood vessel, and upon inflation, exerts a force on the device, bringing it into intimate contact with the plaque layer.
11. The cell suspension delivery device of claim 9 , wherein the tubular member is deformed by application of a mechanical force from a conical member in slidable relationship with the device.
12. 10. The cell suspension delivery device of claim 9, wherein the tubular member is formed into a three-dimensional structure joined at opposite ends of the longitudinal axis, and the ends are pulled together or apart by application of a longitudinal axis force provided by a slide wire, causing the device to expand in the axial direction when force is applied to the wire in a first direction and causing the device to contract in the axial direction when force is applied to the wire in a second direction.
13. 10. The cell suspension delivery device of claim 9, further comprising a catheter connected to the device, the catheter having a lumen in fluid communication with the lumen of the device.
14. a. introducing a delivery device via percutaneous access to a blood vessel and positioning said delivery device adjacent to the tissue to be treated; b. mechanically penetrating the vessel wall adjacent to the tissue to be treated; c. delivering, under pressure, a quantity of cells in a suspension via the delivery device to the tissue to be treated; and c. withdrawing said delivery device.
15. the tissue to be treated is a blood vessel; a. the further step of mechanically disrupting or penetrating the plaque layer after positioning said delivery device, and after step b.
15. The method of claim 14, comprising the further step of: b. delivering, under pressure, a quantity of cells in suspension via the delivery device to one or more of the plaque, intima, subintimal space, media, adventitia, or peradventitial space.
16. the tissue to be treated is an aneurysm; a. the further step of introducing said delivery device via percutaneous access to a paired vein and positioning said delivery device adjacent to said aneurysm of a paired artery; b. the further step of mechanically penetrating the venous walls of the paired veins proximate to the aneurysm; and c) delivering a quantity of cells in suspension via said delivery device to peri-arterial tissue in proximity to said aneurysm.
Citation Information
Patent Citations
A catheter for intraluminal delivery of therapeutic agents that minimizes therapeutic agent loss
JP2006501869A
